Table 3

Observed/expected number of deaths, SMR, and 95% CI for selected cancers and selected subgroups, 1944–98

		Colorectal cancer	Prostate cancer	Hodgkin’s disease	Multiple myeloma	All leukaemia	NHL
NHL, non-Hodgkin’s lymphoma; ysh, years since hire.
All subjects	Obs/exp	193/177.8	154/148.6	12/10.8	26/27.3	71/61.1	53/53.3
	SMR	109	104	111	95	116	100
	(95% CI)	(94–125)	(88–121)	(58–195)	(62–140)	(91–147)	(75–130)
Ever hourly	Obs/exp	161/150.0	130/127.8	7/9.1	20/23.2	63/51.3	49/44.2
	SMR	107	102	77	86	123	111
	(95% CI)	(91–125)	(85–121)	(31–158)	(53–133)	(94–157)	(82–147)
Never hourly	Obs/exp	32/27.8	24/20.8	5/1.6	6/4.1	8/9.8	4/9.1
	SMR	115	115	305	146	82	44
	(95% CI)	(79–162)	(74–172)	(99–711)	(54–317)	(35–161)	(12–112)
All hourly subjects by years since hire (ysh) and years worked (yrs)
<20 ysh,	Obs/exp	10/12.5	1/5.2	2/3.3	0/1.6	4/7.0	0/4.9
<10 yrs	SMR	80	19	61	0	57	0
	(95% CI)	(38–147)	(1–108)	(7–221)	(0–236)	(16–146)	(0–76)
<20 ysh,	Obs/exp	9/10.9	3/4.0	3/1.7	3/1.5	6/4.4	1/3.6
10+ yrs	SMR	83	75	178	207	136	28
	(95% CI)	(38–157)	(15–218)	(37–519)	(43–605)	(50–296)	(1–155)
20–29 ysh,	Obs/exp	11/11.1	7/7.7	1/0.8	2/1.7	4/4.1	5/3.5
<10 yrs	SMR	99	90	129	117	98	143
	(95% CI)	(49–177)	(36–186)	(3–720)	(14–423)	(27–251)	(46–333)
20–29 ysh,	Obs/exp	35/23.8	12/13.6	1/1.4	6/3.4	19/7.4	11/6.5
10+ yrs	SMR	147	88	70	175	258	170
	(95% CI)	(103–205)	(46–154)	(2–392)	(64–380)	(156–403)	(85–305)
30+ ysh,	Obs/exp	30/26.5	46/29.8	0/0.6	3/4.6	10/8.9	7/8.0
<10 yrs	SMR	113	155	0	65	113	87
	(95% CI)	(76–162)	(113–206)	(0–591)	(13–189)	(54–207)	(35–179)
30+ ysh,	Obs/exp	66/65.2	61/67.4	0/1.4	6/10.3	20/19.6	25/17.7
10+ yrs	SMR	101	90	0	58	102	141
	(95% CI)	(78–129)	(69–116)	(0–271)	(21–126)	(62–158)	(91–208)